Filter By Category
Archives
Share on -
CAROCOVATEIN
Generic Name: CAROCOVATEIN
ABSTRACT -
Carocovatein is an investigational anti-cancer agent currently in early-phase clinical evaluation. Based on its naming convention and structural class, it targets dysregulated intracellular signalling pathways associated with tumour cell proliferation and survival. Detailed mechanistic and clinical data are being generated in ongoing Phase I studies in solid tumours.
DOSAGE -
Dosing regimen is being established in Phase I dose-escalation studies; oral or intravenous administration under evaluation.
SIDE EFFECTS-
- Fatigue
- Nausea
- Decreased appetite
- Diarrhoea
- Elevated liver enzymes
ALLERGIC REACTIONS -
These symptoms may indicate an allergic reaction and require immediate medical attention.
- Hypersensitivity reactions
- Skin rash or urticaria
- Facial swelling
- Anaphylaxis (rare)
DRUG INTERACTIONS-
- CYP3A4-mediated interactions likely
- Avoid concomitant hepatotoxic drugs
- Interaction profile to be fully characterised
PREAUTONS–
- Liver function tests required at baseline and periodically
- Contraception required for both partners during treatment
- Use only in clinical trial settings
- Paediatric and elderly safety data lacking
WARNINGS –
- Hepatotoxicity risk — discontinue if significant ALT/AST elevation
- Embryo-foetal toxicity not excluded
- Report all adverse events through trial pharmacovigilance
Share on -
. Developed by